Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
45.04
+6.17 (15.87%)
At close: Nov 6, 2026, 4:00 PM EST
45.28
+0.24 (0.53%)
After-hours: Nov 6, 2026, 7:30 PM EST
Edgewise Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 68.68 | 61.15 | 41.67 | 86.1 | 21.99 | 15.57 |
Short-Term Investments | 1,675 | 468.96 | 428.5 | 232.3 | 329.95 | 265.22 |
Cash & Short-Term Investments | 1,744 | 530.11 | 470.17 | 318.39 | 351.95 | 280.79 |
Cash Growth | 209.56% | 12.75% | 47.67% | -9.53% | 25.34% | 117.51% |
Prepaid Expenses | 28.58 | 13.28 | 5.31 | 8.6 | 5.05 | 2.98 |
Total Current Assets | 1,772 | 543.39 | 475.48 | 327 | 357 | 283.77 |
Property, Plant & Equipment | 7.55 | 9.22 | 11.07 | 12.69 | 9.85 | 0.91 |
Long-Term Deferred Charges | - | - | 0.26 | 0.3 | 0.25 | - |
Other Long-Term Assets | - | - | - | 0.05 | - | 0.55 |
Total Assets | 1,780 | 552.6 | 486.82 | 340.04 | 367.1 | 285.23 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 9.64 | 6.01 | 5.58 | 4.03 | 6.11 | 3.84 |
Accrued Expenses | 19.36 | 20.35 | 17.29 | 11.77 | 9.87 | 6.68 |
Current Portion of Leases | 1.03 | 1.01 | 1 | 0.98 | 0.61 | - |
Total Current Liabilities | 144.11 | 27.37 | 23.86 | 16.77 | 16.59 | 10.52 |
Long-Term Leases | 2.36 | 2.98 | 3.74 | 4.43 | 3.8 | - |
Other Long-Term Liabilities | 0.89 | - | - | - | - | 0.33 |
Total Liabilities | 147.35 | 30.35 | 27.6 | 21.21 | 20.39 | 10.85 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 1,125 | 1,068 | 837.36 | 563.49 | 492.67 | 351.85 |
Retained Earnings | 513.44 | -546.37 | -378.58 | -244.76 | -144.6 | -76.96 |
Comprehensive Income & Other | -5.6 | 0.68 | 0.42 | 0.1 | -1.36 | -0.51 |
Total Common Equity | 1,633 | 522.26 | 459.22 | 318.83 | 346.72 | 274.38 |
Shareholders' Equity | 1,633 | 522.26 | 459.22 | 318.83 | 346.72 | 274.38 |
Total Liabilities & Equity | 1,780 | 552.6 | 486.82 | 340.04 | 367.1 | 285.23 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 3.38 | 3.99 | 4.74 | 5.41 | 4.41 | - |
Net Cash (Debt) | 1,741 | 526.12 | 465.43 | 312.98 | 347.54 | 280.79 |
Net Cash Growth | 211.27% | 13.04% | 48.71% | -9.94% | 23.77% | 117.51% |
Net Cash Per Share | 14.97 | 5.11 | 5.04 | 4.91 | 6.48 | 7.48 |
Filing Date Shares Outstanding | 109.48 | 107.27 | 95.21 | 93.11 | 63.26 | 49.51 |
Total Common Shares Outstanding | 109.46 | 106.25 | 94.84 | 70.45 | 63.26 | 49.5 |
Working Capital | 1,628 | 516.02 | 451.62 | 310.23 | 340.41 | 273.25 |
Book Value Per Share | 14.92 | 4.92 | 4.84 | 4.53 | 5.48 | 5.54 |
Tangible Book Value | 1,633 | 522.26 | 459.22 | 318.83 | 346.72 | 274.38 |
Tangible Book Value Per Share | 14.92 | 4.92 | 4.84 | 4.53 | 5.48 | 5.54 |
Machinery | 4.88 | 4.88 | 4.54 | 4.25 | 2.26 | 1.61 |
Construction In Progress | - | 0.08 | - | 0.08 | 7.34 | - |
Leasehold Improvements | 9.83 | 9.65 | 9.65 | 8.73 | - | - |